Podcasts about magee womens hospital

When children go through treatment for cancer, there's a risk it could affect their fertility. Pittsburgh is on the cutting edge of something that could help: a process called pediatric fertility treatment. But how does it work for kids who haven't gone through puberty yet? And what's it like to broach this subject with families who've just received a life-altering diagnosis? Amy Jutca, the fertility preservation program navigator at Children's Hospital of Pittsburgh, joins us to talk about helping kids and families with their options. Check here for more about fertility preservation programs at Children's Hospital and Magee-Womens Hospital. Our newsletter is fresh daily at 6 a.m. Sign up here. We're also on Twitter @citycastpgh & Instagram @CityCastPgh! Learn more about your ad choices. Visit megaphone.fm/adchoices

Join Craig as he discusses with LaJuana: Breast Cancer is the #1 leading cause of cancer death of African American Women. Why getting a Mammogram is so important to African American Women? How UPMC is targeting outreach to the African American community to help battle Breast Cancer. Additionally, make sure you listen to our Community Calendar (brought to you by Port Authority Transit Employment) with Debbie Norrell at the end of each of our interviews so you can keep up with what's going on in our Pittsburgh region. Soul Pitt Media's Health & Business Report is sponsored by UPMC, Port Authority Transit, Duquesne Light Co., ThermoFisher Scientific, Pennsylvania's Children's Health Insurance Program (CHIP), and PA Unites Against COVID.

Dr. Richard Beigi, President of UPMC Magee Womens Hospital explains the hospital's new protocols to keep you safe while delivering world-class care.

Dr. Richard Beigi, President of UPMC Magee Womens Hospital explains the hospital’s new protocols to keep you safe while delivering world class care.

Regenerative Medicine Today welcomes Dr. Stephen Emery.  Dr. Emery is an Associate Professor, Department of Obstetrics, Gynecology, & Reproductive Sciences, Maternal Fetal Medicine, at Magee-Womens Hospital of UPMC.  He is also the Director of the Center for Innovative Fetal Intervention at Magee-Womens Hospital of UPMC.   Dr. Emery discusses his research in prenatal treatments. For more [...]

Welcome to the ASCO Daily News podcast. I'm Lauren Davis. And joining me today is Dr. Priya Rastogi, who specializes in the diagnosis, treatment, and prevention of breast cancer at the Magee-Womens Hospital of the University of Pittsburgh Medical Center. And she's also the senior associate medical director for the NSABP Foundation. Today, we're discussing the topic of recurrence among patients with HER2 positive breast cancer, progress and providing more aggressive therapies in early breast cancer for those patients whose cancer is more likely to recur. Namely those with residual invasive disease following taxane and trastuzumab based treatment given before surgery is our area of focus. Dr. Rastogi, welcome to the podcast. Hi, Lauren, happy to discuss the exciting results from the KATHERINE study. We're glad you're here. So as an investigator of the KATHERINE study, I'd like to hear a little bit about some of the findings. So I understand that the study showed that T-DM1 reduced the risk of disease recurring by half compared with trastuzumab in HER2 positive early breast cancer. Yes. So in terms of background information, patients with HER2 positive early breast cancer receiving neoadjuvant treatment had favorable outcomes if they achieve a pathological complete response. But patients with residual breast cancer in the surgical specimen have a higher risk of recurrence. And so that's some of the rationale of how the KATHERINE study was set up. The KATHERINE trial was an open label study with 1,486 patients with HER2 positive early stage breast cancer who received neoadjuvant chemotherapy plus HER2 targeted therapy that included a taxane and trastuzumab followed by surgery. And then all these patients had residual invasive disease in the breast and/or actually in lymph nodes. So within 12 weeks of surgery, patients were assigned to either T-DM1 or to trastuzumab. And as you mentioned, the primary endpoint was IDFS. And so in the KATHERINE study, T-DM1 significantly reduced the risk of developing an invasive disease free survival event by three years by 50%. And this corresponds to an absolute improvement in three year invasive disease free survival of 11 percentage points. So this is really exciting. So the invasive disease free survival rate was 77% with trastuzumab, and it increased to 88.3% with T-DM1. So the KATHERINE trial demonstrates that neoadjuvant therapy can be used to identify patients at increased risk for recurrence based on less than optimal response to standard neoadjuvant therapies who can then benefit by switching to T-DM1. The overall survival analysis has not yet matured. We had a total of 98 deaths, 56 deaths with trastuzumab and 42 with T-DM1 for a hazard rate of 0.7. So clearly, this study will need more follow up. So the FDA approved T-DM1 as adjuvant treatment for this patient population. Do patients have immediate access? Yes, so this is also exciting news that the US FDA approved T-DM1 for the adjuvant treatment in patients with HER2 positive early stage breast cancer with residual invasive disease after neoadjuvant taxane trastuzumab based therapy. The results and approval form the foundation of a new standard of care in patients in this setting. And this should lead to access and availability for patients. Patients should discuss with their physicians and their insurance providers. That's exciting. So one of the things we always think about are side effects. What should specialists tell their patients? Yeah, so as you mentioned, side effects are very important. So the safety profile of T-DM1 is as expected from what has been seen in the metastatic setting in the use of T-DM1. The main adverse events in our study was a decrease in platelet counts, an increase in sensory neuropathy and liver enzymes compared to trastuzumab. Although, these side effects are mostly mild. Fatigue and nausea were also greater. But they were manageable and reversible. So the side effect profile is similar to what had been seen in the metastatic setting and the efficacy is fantastic for this drug. Oh, that's great. Were there any surprises in the results? So the analysis by the subgroups demonstrated that there was a benefit across all the key subgroups. So for example, patients with operable or inoperable cancers at presentation, hormone receptor positive or hormone receptor negative, post neoadjuvant positive or negative nodes, and even patients with very small residual disease all had a tremendous benefit from T-DM1. So this is also very exciting that all the subgroups benefited. So what do you think is on the horizon for breast cancer studies? That is also a very important question. So immunotherapy is a type of cancer treatment which also helps the immune system fight cancer. And immunotherapy has been approved in other cancers. One type of these drugs is atezolizumab, which belongs to a class of drugs known as the checkpoint inhibitors. By inhibiting the checkpoint proteins such as PD-L1 and PD-1, these drugs enhance the ability for the immune cells to attack cancer cells. So recently, the FDA approved atezolizumab in combination with chemotherapy for the initial treatment of women for advanced triple negative breast cancer with PD-L1 positive tumors. So the NSABP Foundation in collaboration with the German Breast Group is conducting a phase III study, it's NSABP B59 [INAUDIBLE], for patients with early stage high risk triple negative breast cancer. And so this trial is evaluating neoadjuvant chemotherapy with atezolizumab or a placebo followed by surgery. Patients then receive an additional six months of either atezo or placebo after surgery. And the co-primary end points are pathological complete response and event free survival. And this study will address if neoadjuvant atezolizumab in combination with neoadjuvant chemotherapy followed by adjuvant atezolizumab will improve outcomes in this high risk patient population. That's fantastic. It sounds like there's a lot of things to look forward to. Again, today, my guest has been Dr. Rastogi. Thank you so much for being on our podcast today. It has been a privilege. And thank you for inviting me to talk about the KATHERINE study. And to our listeners, thank you for tuning in to the ASCO Daily News podcast. If you're enjoying the content, we encourage you to rate us and review us on Apple Podcast.

Our guest today is a healthcare evangelist and international healthcare industry expert. Tanya Abreu pioneered the planning of the first network of freestanding breast health centers in the greater Pittsburgh area and the establishment of more than 75 model women’s health education and primary care clinics around the world. As a healthcare marketing innovator, Tanya is also a successful speaker, author and workshop leader. Tanya’s Background Tanya began her career in education as a business communications professor in the Graduate School of Industrial Management at Carnegie Mellon University. She went to Russia to teach American English at Moscow State University. While there, Tanya got excited about being able to change a healthcare system with terrifying technology into something more humane. She came back to the U.S. to partner with Magee-Womens Hospital in Pittsburgh, where she took part in the transformation of women’s health through branding and outreach. The CEO at Magee, Irma Goertzen, believed women feared coming to the hospital in the inner city for a breast image knowing there was a possibility that she might have cancer. Goertzen believed the hospital’s responsibility was to care for women.  She spent millions setting up freestanding breast care clinics within the communities where the women lived. The clinics eventually expanded to provide pelvic health and heart disease prevention. When Tanya left Magee, she started her own company called Spirit of Women. In this role, Tanya worked with C-suite executives to help them reevaluate how they presented healthcare to women. She is now involved in the Lipstick Alliance movement and is the national director of the Women’s Choice Award. Creating Successful Healthcare Brands for Women According to Tanya, there are distinct differences between men and women when it comes to healthcare. Men are more action-driven. They want to know what they have and what to do. Women often shun wellness care because it takes them away from their families’ needs. It’s not that women fear the disease, they just don’t want to have it now because they must stop what they are doing. Women make more than 85 percent of all healthcare decisions for their family. Tanya says for hospitals and health groups to grow its brand with women, they need to capture the “heart” share of women before the money. The biggest mistakes that healthcare providers make is trying to fix women. Women don’t want to be fixed. They want to be listened to and encouraged. They want to know about the experiences and quality of life other women have had. Taking a grassroots approach to healthcare marketing is paramount. Patient testimonials, community events and social media are more important to women than advertisements and billboards. It’s all about patient and community experience communications. With 30 years in this industry, Tanya has always believed hospitals that support and encourage women are the ones that will have their loyalty and generate revenue. After her own experience with cancer, she realized there was more. She realized that much of what she had been doing was lip service to women wanted to hear. She didn’t want to be controlled, she wanted to be encouraged. She wanted hope, not more medication. The Lipstick Alliance These days, Tanya is working with hospitals to form the Lipstick Alliance. Statistics show that 83 percent of women put on lipstick daily to make them feel good. The Lipstick Alliance is about wellness every day for women. Tanya wants it to be a movement that gets women thinking about doing something healthy every time they put on lipstick, lip gloss or chapstick. She hopes that one day the lipstick icon will be as recognizable as the red dress is for heart health and the pink ribbon is for breast cancer awareness. The Lipstick Alliance is about wellness every day for women. The national program is market exclusive, so there can only be one hospital per market in the U.S. Hospitals don’t have to apply, but they must be focused on wellness. They must also agree to use the organization’s 1-4-12 strategy which includes templates, education materials, content and a national awards program for organizations that build relationships with women that result in increased revenues. Tanya says they are reducing the fee for the first 20 hospitals and that the program is typically less than $3,000/month. The Patient Experience Two things are pivotal in healthcare branding for women. She must feel she is being listened to and heard, and not just filling out a bunch of paperwork. She also needs to feel more encouraged when she leaves the hospital or clinic than when she came in. And the experience must be positive. As an example, Tanya says heart disease is the number one killer of women, yet one in five women in their 50s have had a baseline heart evaluation.  Why?  She says it is because women fear the results. Healthcare groups and hospitals need to find ways to educate and motivate women in a fun way.  Among her many ideas, Tanya says to invite women to a heart day event at a hospital where women can get a free echo-cardiogram. If the hospital is part of the Lipstick Alliance, they can hand out free lipstick when they are done. Wellness Care is in Vogue Hospitals can’t continue to be acute-care facilities. Tanya says they need to start focusing on wellness, incentivizing doctors and providing telemedicine, but only if it is part of a total wellness experience. People have a tendency not to tell everything to a healthcare provider online. Without complete records of the patient, diagnosis can be risky and often incorrect. Women’s Choice Awards Tanya’s newest role is as the national director of the Women’s Choice Awards. The award is third-party verified and 100 percent objective about a company or hospital’s quality measures in patient care and service lines. The seal says the organization has been approved by women and has the objective standards of quality and healthcare capabilities for patient satisfaction. Connect with Tanya Phone: 561-358-5230 Email: tanya@optimisticmedicinegroup.com LinkendIn: @tanyaabreu Facebook: Lipstick Alliance Website: www.womenschoiceaward.com    

Date: May 3, 2012 Featuring: Maureen Bisognano, President and CEO, Institute for Healthcare Improvement, Co-author, Pursuing the Triple Aim Charles Kenney, Writer and Journalist, Co-author, Pursuing the Triple Aim Alide Chase, Senior Vice President, Medicare Clinical Operations and Population Care, Kaiser Foundation Health Plan, Inc., and Kaiser Foundation Hospitals Anthony M. DiGioia, MD, Renaissance Orthopaedics; Medical Director, Bone and Joint Center, Magee-Womens Hospital and PFCC Partners – Innovation Center of UPMC George E. Kerwin, FACHE, President and Chief Executive Officer, Bellin Health Patricia A. McDonald, Vice President, Technology and Manufacturing Group and Director of Product Health Enhancement Organization, Intel Corporation Diane K. Miller, MBA, Vice President, Virginia Mason Medical Center, Executive Director, Virginia Mason Institute Rebecca Ramsay, RN, MPH, Director, Care Support Manager, CareOregon Brian H. Rank, MD, Medical Director, HealthPartners Medical Group, HealthPartners, Inc. Marci Sindell, Chief External Affairs Officer, Atrius Health and Harvard Vanguard It isn’t always easy to tell the story of improving health care in the US. An awful lot of the answers and promising solutions fly under the radar screen and get drowned out by politics and policy debates. That’s why Maureen Bisognano and Charlie Kenney decided to move about the country this past year and capture just a small sample of the innovation underway that promises to move health reform forward… even as national debates rage on. What the organizations featured in Maureen and Charlie’s new book, Pursuing the Triple Aim: Seven Innovators Show the Way to Better Care, Better Health, and Lower Costs, share in common is this clear-eyed view that the status quo is not sustainable and that new models to simultaneously improve health, improve health care, and reduce per capita costs aren’t just needed, they’re needed urgently. The organizations whose stories you can read about in the new book and that you’ll hear about on WIHI are currently in the trenches and represent a leading spear of change, tackling some of the hardest issues ever for health care. All the people associated with the work are eager to share whatever they can with as many as they can. WIHI host Madge Kaplan pulls together the program’s first ever audio “book party” with enough time to hear from all the contributors and also ask questions and engage in discussion. A special note to improvers in other countries and around the globe: many of you have been part of IHI’s Triple Aim prototyping initiative for the past several years or have crafted initiatives of your own. Work outside the US is also critical and vital to everyone’s learning and everyone is encouraged to participate in this WIHI discussion.

Date: September 8, 2011 Featuring: Lucile O. Hanscom, Executive Director, Picker Institute Dale Shaller, MPA, Principal, Shaller Consulting Group Martha Hayward, Lead for Public-Patient Engagement, Institute for Healthcare Improvement Gaye Smith, Chief Patient Experience and Service Officer, Vanderbilt University Medical Center Anthony M. DiGioia, MD, Founder, The Orthopaedic Program and Innovation Center, Magee-Womens Hospital of UPMC Most of us are familiar with the National Quality Forum’s list of Serious Reportable Events in health care — often referred to as “Never Events.” There’s a wide consensus that everything from performing surgery on the wrong patient or wrong site, to a medication error-induced death, to a physical assault aren’t only tragic and harmful, they are not supposed to happen. Period. It’s a strong statement about patient safety and what the system as a whole should not be willing to tolerate. And, by extension, it’s a call to action to do better and to take care of patients differently so that terrible things do not occur.  There are, of course, many ways to draw a line in the sand or to envision the health care system patients deserve and that providers want to work in. One of the most innovative in the last few years has been the Picker Institute’s development of a concept they’ve dubbed “Always Events®.” First conceived in 2009, Always Events®are activities and processes that should routinely be part of patient care and the patient and family experience, to ensure optimal communication, discharge, handoffs, transitions, health literacy, and more.WIHI welcomes the Picker Institute’s Executive Director, Lucile Hanscom; consultant Dale Shaller, who has an extensive history developing benchmarks and measurement systems for patient-centered care; Martha Hayward, who has been working with IHI to help shape public and patient engagement, drawing on her own history as a patient and as a strong and effective leader in Massachusetts; and dynamic leaders from two organizations that have received Always Events Challenge Grants: Gaye Smith of Vanderbilt University Medical Center and Tony DiGioia of the University of Pittsburgh Medical Center (UPMC).Dr. DiGioia’s groundbreaking improvements at UPMC are anchored in a first of its kind patient- and family-centered methodology. Picker’s support is helping to integrate these processes into the hospital’s transplant program. The grant-funded work at Vanderbilt, under Gaye Smith, is targeting better communication and collaboration between patients, family members, and providers to prevent patient falls during hospital stays.

123: As co-author of “The New York Times” best-selling book “In an Instant: A Family’s Journey of Love and Healing”, Lee Woodruff garnered critical acclaim for the compelling and humorous chronicle of her family’s journey to recovery following her husband’s, journalist Bob Woodruff, roadside bomb injury in Iraq. Appearing on national television and as keynote speakers since the February, 2007 publication of their book, the couple has helped put a face on the serious issue of traumatic brain injury among returning Iraq war veterans as well as the millions of Americans who live with this often invisible, but life-changing affliction. - Fertility help for military families - Helping our wounded warriors start a family - Providing fertility support for our wounded warriors - Reintegrating our wounded warriors into their community  They have founded the non-profit Bob Woodruff Foundation to assist injured service members and their families in healing from the wounds of war, having raised $27 million and investing in grassroots organizations and programs around the country that are helping veterans successfully reintegrate into their communities and receive critical long-term care.  Lee is a contributing editor for “Working Mother” magazine and a contributing national television network reporter and runs a media training/speaker presentation business for clients who want to polish their performance. Her best-selling book “Perfectly Imperfect - A Life in Progress” was followed by her first novel “Those We Love Most” which became a “New York Times” best-seller and won the Washington Irving Book Award for fiction.  A freelance writer, Leef has penned numerous personal articles about her family and parenting that have run in magazines such as “Ladies Home Journal”, “Real Simple”, “MORE”, “Good Housekeeping”, and Parade. A trustee and alumnus of Colgate University and an avid lover of the Adirondack region, Lee lives  in Westchester County, New York, with her husband and four children.  For much more information on Lee Woodruff, please visit http://www.leewoodruff.com/about-me.  For much more information on Bob Woodruff, please visit http://www.bobwoodrufffoundation.org.  BIOGRAPHICAL INFORMATION on nationally-renowned fertility specialist Dr. Gilbert Mottla Dr. Gilbert L. Mottla, M.D., is board-certified in obstetrics and gynecology as well as reproductive endocrinology and infertility. He treats many U.S. veterans in his Annapolis, Maryland practice and is a member of the American Society for Reproductive Medicine.  Having received his medical degree from Boston University School of Medicine, Dr. Mottla completed his internship and residency in obstetrics and gynecology at Magee-Womens Hospital, University of Pittsburg and completed a two-year fellowship in reproductive endocrinology and infertility at The George Washington University School of Medicine. Dr. Mottla is currently a clinical assistant professor of obstetrics and gynecology at Georgetown University.  Recently recognized by “Washingtonian” magazine and “What’s Up Annapolis” magazine in the top doctor’s edition for reproductive endocrinology and infertility, Dr. Mottla sees and consults with patients who need care in all areas of both infertility and reproductive endocrinology. His particular area of interest is in the evaluation and care of couples utilizing gestational surrogacy and egg donation.  For much more information on Dr. Mottla, please visit http://www.shadygrovefertility.com/doctors/mottla. When you're planning to leave the military visit USAA's separations tools and advice for information on readiness and making a successful transition. http://www.veteranonthemove.com/leavingthemilitary The Veteran On the Move podcast has published over 100 episodes giving listeners the opportunity to hear in-depth interviews conducted by host Joe Crane featuring the people, programs and resources to assist veterans in their transition to entrepreneurship:  Marine Corps,

Host: Prathima Setty, MD Guest: Draion M. "Dr. Drai" Burch, DO Female sexual dysfunction (FSD) occurs in about 20 - 60% of patients. FSD is common problem but how comfortable are clinicians in disussing this with their patients? Host Dr. Prathima Setty welcomes Dr. Draion "Dr. Drai" Burch, obstetrician-gynecologist and teaching faculty member at Magee-Womens Hospital of The University of Pittsburgh Medical Center. Dr. Drai reviews the symptoms and causes of FSD and how he counsels patients on FSD. Dr. Drai is also Clinical Assistant Professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of Pittsburgh School of Medicine.

Host: Prathima Setty, MD Guest: Draion M. "Dr. Drai" Burch, DO What does transgender mean? What are common health issues found in transgender patients? Host Dr. Prathima Setty welcomes Dr. Draion M. Burch, also known as "Dr Drai". Dr. Drai will address these questions, as well as, information on screening, hormone therapy, and resources available for clinicians, specifically on how to make their offices transgender-friendly. Dr. Burch is a practicing physician and teaching faculty member at Magee-Womens Hospital of The University of Pittsburgh Medical Center. Dr. Drai is the Founder and Chief Medical Advisor of DrDrai.com, where he discusses actionable ideas and real-world strategies to help women take control of their health.